•Used to prevent and treat breakthrough chemotherapy-induced emesis when given alone and in combination with other anti-emetic drugs20 including patients receiving palliative care21, 22•For example, a significant improvement in nausea reported when given together with 5-HT3 and NK1 receptor antagonists23, 24. The gene discussed is HTR3A; the disease is Nausea and vomiting.